Boehringer Ingelheim Invests 46 Million in R&D in 2022 in Spain

Boehringer Ingelheim increases its research budget in Spain. The German pharmaceutical group invested €46 million in research, development, and innovation (R+D+i) projects in 2022 in its Spanish subsidiary, compared to  €42.6 million the previous year, which translates into an increase of 8.2% year-on-year, as reported by the group in a statement.

The Spanish subsidiary of the pharmaceutical company has participated in 49 international clinical trials in 2022, which translates into a year-on-year rise of 7.4%. Of these trials, 16 belong to the area of ​​oncology and are in phase I, while there are another 25 in phase II that are for various conditions, including mental health, cardio metabolism, oncology, respiratory, and immunology. The studies have included more than 349 patients from 58 health centers, of which up to 178 patients correspond to people spread throughout the national territory.

On the other hand, the company has participated in fifteen studies of molecules that are already on the market. In these analyses, attention has been focused on analyzing the quality of life or post-authorizations, in addition to pharmacoeconomic studies. The company currently has a hundred projects in different research phases and 75% of these belong to the first molecule, with 50% having sufficient potential to become relevant future advances.

If you want to read more about Boehringer Ingelheim and to find the most important business news of the day, download for free our companion app Born2Invest.

Boehringer Ingelheim recorded sales of €24.1 billion in 2022

The company develops its research activity in the territory through three international hubs located in Sant Cugat del Vallès (Barcelona), which are: Its HUB, Regulatory Affairs, and Delivery Unit. The company headquarters in Sant Cugat has around 1,600 collaborators from 41 different nationalities. This year the company has invested around €1.2 million in internal training.

In 2022, the Spanish subsidiary registered an increase of 11.3% in net sales compared to the previous year, with drugs for the treatment of cardiovascular, metabolic, and respiratory diseases being the products that generated the most net sales.

The financial director of the group in Spain, Torsten Eschenbrenner, has highlighted that “competitiveness and profitability are the basis for discovering new innovative therapies, growing in the medium and long term and investing more and more in new technologies that improve the lives of more patients .”

Boehringer Ingelheim reached a sales figure of  €24.1 billion in 2022, which translates into a year-on-year rise of 10.5%. Meanwhile, investments in R&D projects reached €5 billion.

__

(Featured image by felixioncool via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.